Home › Trials › NCT06625320

Evaluating a new treatment for metastatic pancreatic cancer

RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of Daraxonrasib (RMC-6236) Versus Investigator's Choice of Standard of Care Therapy in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Phase 3 Interventional Revolution Medicines, Inc. · NCT06625320

This study is testing a new drug called RMC-6236 to see if it can help people with advanced pancreatic cancer live longer and feel better compared to standard chemotherapy.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment460 (estimated)
Ages18 Years and up
SexAll
SponsorRevolution Medicines, Inc. Industry-sponsored
Drugs / interventionschemotherapy
Locations47 sites (Gilbert, Arizona and 46 other locations)
Trial IDNCT06625320 on ClinicalTrials.gov

What this trial studies

This global, randomized, open-label Phase 3 study aims to assess the safety and efficacy of RMC-6236, a novel RAS(ON) inhibitor, in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). Participants will be randomly assigned to receive either RMC-6236 or the investigator's choice of standard chemotherapy. The primary focus is to determine if RMC-6236 can improve progression-free survival (PFS) or overall survival (OS) compared to standard treatments. Eligible patients must have measurable disease and documented RAS mutation status.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with histologically confirmed metastatic PDAC who have previously received one line of chemotherapy.

Not a fit: Patients with prior therapy involving direct RAS-targeted treatments or those with central nervous system metastases may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option that improves survival outcomes for patients with metastatic pancreatic cancer.

How similar studies have performed: While this approach is novel in targeting RAS mutations specifically, similar studies have shown promise in treating other cancers with targeted therapies.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* At least 18 years old and has provided informed consent.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Histologically or cytologically confirmed PDAC with metastatic disease.
* Measurable disease per RECIST 1.1.
* Adequate organ function (bone marrow, liver, kidney, coagulation)
* Documented RAS mutation status, either mutant or wild-type. RAS mutations defined as nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61).
* Able to take oral medications.

Exclusion Criteria:

* Prior therapy with direct RAS-targeted therapy (eg. degraders and/or inhibitors).
* History of or known central nervous system metastatic disease.
* Any conditions that may affect the ability to take or absorb study treatment
* Major surgery within 4 weeks prior to randomization.
* Patient is unable or unwilling to comply with protocol-required study visits or procedures

Where this trial is running

Gilbert, Arizona and 46 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Pancreatic CancerPDACPDAC - Pancreatic Ductal AdenocarcinomaPancreatic Ductal AdenocarcinomaRASKRASNRASHRAS
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.